Volume 14, Issue 4 , Pages 237-246, December 2006
Homeopathic arnica therapy in patients receiving knee surgery: Results of three randomised double-blind trials☆
Summary
Objectives
We investigated the effectiveness of homeopathic Arnica montana on postoperative swelling and pain after arthroscopy (ART), artificial knee joint implantation (AKJ), and cruciate ligament reconstruction (CLR).
Design
Three randomised, placebo-controlled, double-blind, sequential clinical trials.
Setting
Single primary care unit specialised in arthroscopic knee surgery.
Participants
Patients suffering from a knee disease that necessitated arthroscopic surgery.
Interventions
Prior to surgery, patients were given 1
×
5 globules of the homeopathic dilution 30× (a homeopathic dilution of 1:1030) of arnica or placebo. Following surgery, 3
×
5 globules were administered daily.
Primary outcome measures
The primary outcome parameter was difference in knee circumference, defined as the ratio of circumference on day 1 (ART) or day 2 (CLR and AKJ) after surgery to baseline circumference.
Results
A total of 227 patients were enrolled in the ART (33% female, mean age 43.2 years;), 35 in the AKJ (71% female, 67.0 years), and 57 in the CLR trial (26% female; 33.4 years). The percentage of change in knee circumference was similar between the treatment groups for ART (group difference Δ
=
−0.25%, 95% CI: −0.85 to 0.41, p
=
0.204) and AKJ (Δ
=
−1.68%, −4.24 to 0.77, p
=
0.184) and showed homeopathic arnica to have a beneficial effect compared to placebo in CLR (Δ
=
−1.80%, −3.30 to −0.30, p
=
0.019).
Conclusions
In all three trials, patients receiving homeopathic arnica showed a trend towards less postoperative swelling compared to patients receiving placebo. However, a significant difference in favour of homeopathic arnica was only found in the CLR trial.
Keywords: Randomised clinical trial, Homoeopathy, Arnica, Arthroscopy, Artificial knee joints, Cruciate ligament reconstruction
To access this article, please choose from the options below
☆ This trials were funded by the Karl und Veronica Carstens Foundation, a member of the Stifterverband fuer die deutsche Wissenschaft. Trial medication was manufactured by DHU in Karlsruhe, Germany.
PII: S0965-2299(06)00041-0
doi:10.1016/j.ctim.2006.04.004
© 2006 Published by Elsevier Inc.
Volume 14, Issue 4 , Pages 237-246, December 2006
